Insulet Corporation is a publicly traded medical device company listed on NASDAQ under the ticker PODD. Founded in 2000, the company specializes in developing and commercializing tubeless, wearable insulin delivery systems for diabetes management. Its flagship product line, Omnipod, includes the Omnipod 5, recognized as the world's first tubeless automated insulin delivery system controlled by a smartphone and the most prescribed such system in the United States.
The company operates across North America, Europe, the Middle East, and Asia Pacific, serving over 600,000 customers in 25 countries. For the fiscal year reported, Insulet generated revenue of $2.1 billion. Its technical work spans medical devices, wearable technology, automated insulin delivery, and smartphone-controlled systems.
Insulet's stated mission is to make diabetes a smaller part of life for its community of users, whom it refers to as 'Podders.' The company has articulated a focus on purpose-driven innovation and sustainable, responsible growth within the healthcare and medical devices sector.
